Literature DB >> 16000986

Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.

Paolo Castellucci1, Cristina Nanni, Mohsen Farsad, Lapo Alinari, Pierluigi Zinzani, Vittorio Stefoni, Giuseppe Battista, Daria Valentini, Cinzia Pettinato, Mario Marengo, Stefano Boschi, Romeo Canini, Michele Baccarani, Nino Monetti, Roberto Franchi, Lucia Rampin, Stefano Fanti, Domenico Rubello.   

Abstract

OBJECTIVE: To evaluate the prevalence and scan interpretation criteria useful in identifying non-tumoural F-FDG focal uptakes (potential pitfalls) in patients who had been previously treated for a malignant lymphoma studied by positron emission tomography (PET). MATERIALS: Nine hundred and ninety-six consecutive PET scans obtained in 706 patients with malignant lymphoma were reviewed. All patients had been previously treated by first-line chemo-radiotherapy, plus surgery when required, and were then studied by FDG PET to investigate suspected recurrence at doubtful or inconclusive conventional radiological imaging (ultrasound, computed tomography, magnetic resonance imaging). PET was obtained with patients in the fasted condition and after i.v. injection of 370 MBq of F-FDG; imaging was acquired 60-90 min later. In patients with focal FDG uptake the final diagnosis was reached on the basis of histological findings or long-term follow-up.
RESULTS: Thirty-one of 134 PET scans (23.1%) showing focal FDG uptake were diagnosed as non-tumoural radiotracer uptake, related to the presence of brown fat in seven cases, thymic hyperplasia in five, muscles contraction in four, lymph node unspecific inflammation in four, mediastinal/pulmonary unspecific inflammation in four, gastritis in two, colitis in two, bacterial abscess in one, lactating breast in one, and herpes zoster in one. Each of the above cited situations has been reported in the literature, generally in the form of sporadic reports, as a potential cause of misinterpretation (false positive) in reading a PET scan with the potential for incorrect patient management. An accurate diagnosis in these patients was important for the following therapeutic decision making.
CONCLUSIONS: In the whole series of patients with treated malignant lymphoma, the prevalence of non-tumoural FDG focal uptake during follow-up was relatively low (3.1%); conversely, it was relatively high when considering the sub-group of 'positive' PET only (23.1%). The importance of knowing these situations in order to avoid misinterpretation in reading PET scans needs to be emphasized. In this light, an accurate patient's history and a skilful nuclear medicine physician are very important factors. For the same purpose, it is reasonable to think that the use of hybrid PET/CT tomographs could also play an important role in helping to identify non-tumoural FDG focal uptake.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000986     DOI: 10.1097/01.mnm.0000171781.11027.bb

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  19 in total

1.  Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features.

Authors:  A Surov; H-J Holzhausen; A Wienke; J Schmidt; C Thomssen; D Arnold; K Ruschke; R-P Spielmann
Journal:  Br J Radiol       Date:  2012-06       Impact factor: 3.039

2.  Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.

Authors:  A Orlacchio; O Schillaci; E Gaspari; F Della Gatta; R Danieli; F Bolacchi; C Ragano Caracciolo; A Mancini; G Simonetti
Journal:  Radiol Med       Date:  2012-02-10       Impact factor: 3.469

Review 3.  PET in lymphoma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 4.  Rethinking clinical response and outcome assessment in a biologic age.

Authors:  Bruce D Cheson
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

Review 5.  Promise and pitfalls of quantitative imaging in oncology clinical trials.

Authors:  Brenda F Kurland; Elizabeth R Gerstner; James M Mountz; Lawrence H Schwartz; Christopher W Ryan; Michael M Graham; John M Buatti; Fiona M Fennessy; Edward A Eikman; Virendra Kumar; Kenneth M Forster; Richard L Wahl; Frank S Lieberman
Journal:  Magn Reson Imaging       Date:  2012-08-13       Impact factor: 2.546

6.  Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.

Authors:  Ashish Rai; Loretta J Nastoupil; Jessica N Williams; Joseph Lipscomb; Kevin C Ward; David H Howard; Daniel Lee; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2016-11-10

7.  Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.

Authors:  Amir Sabet; Carsten Meyer; Anas Aouf; Amin Sabet; Shahab Ghamari; Claus C Pieper; Karin Mayer; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-29       Impact factor: 9.236

8.  Herpes zoster infection mimicking pelvic lymph node metastasis on FDG-PET/CT in a patient with cervical cancer.

Authors:  Kazutaka Harashima; Shiro Watanabe; Nanase Okazaki; Daisuke Endo; Yuko Uchiyama; Fumi Kato; Kenji Hirata; Kohsuke Kudo
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021

Review 9.  [Imaging findings of intramammary malignant lymphoproliferative disease].

Authors:  S Wienbeck; H J Meyer; A Surov
Journal:  Radiologe       Date:  2018-10       Impact factor: 0.635

Review 10.  PET/CT imaging: what radiologists need to know.

Authors:  M Benamor; L Ollivier; H Brisse; G Moulin-Romsee; V Servois; S Neuenschwander
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.